Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.55 |
| ▸ | GABRD | O14764 | 2/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.55 |
| ▸ | GABRE | P78334 | 2/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.54 |
| ▸ | CPA3 | P15088 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075789 | 0.85 | GABRP (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22775321 | 0.80 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14780595 | 0.80 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25354508 | 0.80 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29604446 | 0.80 | GABRP (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7048054 | 0.77 | FOLH1 (0.70) | FOLH1CPA3 | |
| SCHEMBL4007106 | 0.77 | CPB2 (0.71) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31688543 | 0.75 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25357726 | 0.75 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25357730 | 0.75 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | claimed |
| WO-2009082340-A1 | METHOD FOR MONITORING THE PROGRESSION OF FIBRINOLYSIS'646 | ASTRAZENECA AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-7071175-B1 | Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| EP-1180098-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066557-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | BPGM, PLG, FGB | GABRP 162/4885GABRD 714/4885GABRA1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.